Infantilis haemangioma: klinikai és demográfiai                     jellemzők, kezelési-gondozási tapasztalatok

Csoma, Zsanett; Dalmády, Szandra; Ábrahám, Rita; Rózsa, Tamás; Rácz, Katalin; Kemény, Lajos

doi:10.1556/650.2017.30838

Cited by 12 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While most of these lesions are asymptomatic and subside by the age of 5 years, complications may arise, including painful bleeding, ulceration or disfiguration ( 2 , 3 ). IH may also induce mental distress to the parents and children ( 4 ). An early intervention is required in such cases to prevent future complications.…”

Section: Introductionmentioning

confidence: 99%

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

Liu

Song

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Infantile haemangioma (IH) is a benign vascular tumour type that occurs in 3-10% of infants. In the present meta-analysis, previous studies comparing clinical outcomes, including the recovery rate and haemangioma activity score (HAS), adverse effects and relapse rates, were compared between patients treated with atenolol and those treated with propranolol for IH. A systematic search in various databases, including Medline, Cochrane Controlled Register of Trials, ScienceDirect and Google Scholar from inception until July 2019 was performed. The Cochrane risk of bias tool was used to assess the quality of published trials. A meta-analysis with a random-effects model and reported pooled mean differences (MD) or odds ratios (OR) with 95% CIs was performed. In total, 8 studies including 608 participants were analyzed. Only 2 studies were randomized controlled trials, while the majority of studies had low or unclear bias risks. Except for the response to medication (pooled OR=1.49; 95% CI, 0.85-2.18), all other outcomes (HAS, adverse reactions and relapse rate) were better for the atenolol group than the propranolol group. Atenolol resulted in better HAS (pooled MD=0.16; 95% CI,-0.42 to 0.73). Propranolol had more adverse reactions (pooled OR=2.17; 95% CI, 0.93-5.06) and a higher relapse rate (pooled OR, 1.67; 95% CI, 0.44-6.41) when compared to atenolol. However, these findings were not statistically significant. The results of this analysis suggest that atenolol may be non-inferior to propranolol and may offer advantages, including lower adverse reactions and relapse rates.

show abstract

Section: Introductionmentioning

confidence: 99%

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

Liu

Song

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Infant hemangioma (IH) is a benign neoplasm commonly seen in childhood, which is more common in premature infants and infants with low birth weight (Smith et al, 2017). There are three distinct clinical histological stages in IH: the early proliferative stage, when undeveloped blood vessels are rapidly growing; plateau stage and final regressive stage, with scattered capillaries and large drainage vessels (Csoma et al, 2017). IH is characterized by spontaneous regression of blood vessels.…”

Section: Introductionmentioning

confidence: 99%

LncRNA OIP5-AS1 Promotes the Proliferation of Hemangioma Vascular Endothelial Cells via Regulating miR-195-5p/NOB1 Axis

et al. 2019

View full text Add to dashboard Cite

Background: Hemangioma, which is a benign vascular neoplasm, has been demonstrated to be the most common tumor of infancy, resulting from aberrant proliferation of endothelial cells and pericytes. Objective: The aim of this study was to determine the role of lncRNA OIP5-AS1 on the proliferation and metastasis of human hemangioma endothelial cells (HemECs). Methods: In this study, we examined the expression of OIP5-AS1 and miR-195-5p in hemangiomas patients. The effects of knockdown or ectopic expression of OIP5-AS1 on the viability, proliferation and apoptosis of HemECs were explored. Rescue assays were performed to explore the effects of OIP5-AS1/miR-195-5p/NOB1 axis on biological behaviors in the HemECs. Results: It was found that OIP5-AS1 was overexpressed in both hemangioma tissues and HemECs cells. OIP5-AS1 knockdown suppressed the proliferation, migration, and invasion of HemECs cell, while overexpression of OIP5-AS1 had opposite effects LncRNA OIP5-AS1 acted as a ceRNA through binding with miR-195-5p to upregulate NOB1 in HemECs. Conclusion: Taken together, lncRNA OIP5-AS1 acted as a ceRNA to drive proliferation, migration and invasion of HemECs through regulating miR-195-5p/NOB1 axis.

show abstract

“…Este tratamiento suele estar indicado cuando existe ulceración, sangrado, infección, afectación ocular o de vía aérea, y/o por razones cosméticas, como el compromiso extenso de la región facial [5][6][7]. Además de estas eventuales complicaciones, estudios han evidenciado que el hemangioma infantil puede afectar la salud mental, tanto de los niños como sus familias [8,9]. Dentro de las distintas opciones de tratamiento actualmente disponibles el propranolol, un betabloqueante no selectivo, representa la terapia usualmente considerada como de primera línea [2,9,10].…”

Section: Problemaunclassified

Oral atenolol compared to oral propranolol for infantile hemangioma

Meza Viteri,

Aranibar

2023

Medwave

View full text Add to dashboard Cite

Introduction Infantile hemangioma is the most frequent benign vascular tumor in childhood, with an incidence of 3 to 10%. When patients require treatment, oral propranolol, a non-selective lipophilic beta-blocker, is usually considered the therapy of choice. However, its use has been associated with several adverse events related to its β-2 action and its ability to cross the blood-brain barrier. Because of this, oral atenolol, a hydrophilic β-1 receptor-selective beta-blocker, may represent a valid treatment alternative. Nonetheless, there is still controversy regarding the efficacy and safety of atenolol when compared with propranolol as monotherapy for this condition. Methods We searched Epistemonikos, the largest database of systematic reviews in health science, which is maintained by screening multiple sources of information, including MEDLINE/PubMed, EMBASE, and Cochrane, among others. Data were extracted from the identified reviews, data from the primary studies were analyzed, a meta-analysis was performed, and a summary table of the results was prepared using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method. Results Nine systematic reviews were identified, including 10 primary studies and three randomized trials. The three randomized trials were included in the analysis of this investigation. Conclusion The use of oral atenolol compared with oral propranolol as monotherapies may result in little or no difference in terms of likelihood of complete remission, decrease in Hemangioma Activity Score, likelihood of post-treatment relapse, and risk of adverse events and severe adverse events, in infantile hemangioma (low certainty of evidence).

show abstract

Infantilis haemangioma: klinikai és demográfiai jellemzők, kezelési-gondozási tapasztalatok

Cited by 12 publications

References 27 publications

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

LncRNA OIP5-AS1 Promotes the Proliferation of Hemangioma Vascular Endothelial Cells via Regulating miR-195-5p/NOB1 Axis

Oral atenolol compared to oral propranolol for infantile hemangioma

Contact Info

Product

Resources

About